180 Life Sciences's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of 180 Life Sciences (ATNF) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: 180 Life Sciences vs Its Competitors
- TTM: Trailing 12-month revenue of 11M vs 483,014M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-49.3% annualized vs trailing 12 months), vs holding steady (+1.9%) for its tracked peer group.
- Profitability: Its -939.1% net margin compares with 11.8% for the peer group.
- Peer revenue share: 180 Life Sciences accounted for 0.0% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $2.69M compares with $1.04M for the peer group (2.6x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ATNF Sales vs. its Competitors, Q2 2026
With a net margin of -939.05 %, 180 Life Sciences reported lower profitability than its competitors (11.75 %).
180 Life Sciences generated 0.00 % of the combined sales of its peer group.
API endpoints for this dataset
180 Life Sciences vs. its Competitors, Q2 2026
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in 180 Life Sciences reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across 180 Life Sciences and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| 180 Life Sciences Corp | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across 180 Life Sciences's competitor groups requires a Commercial License.
180 Life Sciences's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| 180 Life Sciences Corp | - | - | - | No |
| Competitors combined (112) | ||||
| High-Confidence Competitors (1) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ATNF Stock Performance relative to its Competitors
ATNF Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 3 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 4 | Prelude Therapeutics Inc | 282.9% | Outperformed |
| 5 | Kiniksa Pharmaceuticals International Plc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for 180 Life Sciences's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
180 Life Sciences's Comment on Competition and Industry Peers
Publicly Traded Peers of 180 Life Sciences Corp
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 180 Life Sciences Corp |
120.15 | 10.77 |
 Johnson and Johnson |
690,774.55 | 99,335.00 |
 Beone Medicines Ltd |
628,232.68 | 6,128.24 |
 Abbvie Inc |
519,727.60 | 66,014.00 |
 Merck and Co Inc |
367,313.70 | 66,569.00 |
 Astrazeneca Plc |
295,827.18 | 58,739.00 |
| SUBTOTAL | 3,793,810.59 | 637,317.50 |
Sign in to see all competitors of 180 Life Sciences Corp.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on 180 Life Sciences Corp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
180 Life Sciences's Competitors Named by the Company
Competitive relationships identified from 180 Life Sciences reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Hebrew University of Jerusalem | Company report | 85% |
| Oxford | Company report | 85% |
| Auxilium | Company report | 85% |
| Medicines Co | Company report | 85% |
Company report basis, confidence, active dates and source counts for 180 Life Sciences's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
180 Life Sciences's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for 180 Life Sciences Corp.
180 Life Sciences's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| 180 Life Sciences Corp | 120 | 2,692,742 | -147,122,114 |
| Johnson and Johnson | 690,775 | 705,504 | 114,311 |
| Beone Medicines Ltd | 628,233 | 510,686 | 54,642 |
| Abbvie Inc | 519,728 | 1,158,140 | 181,509 |
| Merck and Co Inc | 367,314 | 887,587 | 42,267 |
| Astrazeneca Plc | 295,827 | 706,847 | 123,141 |
| PEERS TOTAL | 3,793,690 | 1,035,631 | 137,372 |
Sign in to see all peers for 180 Life Sciences Corp.
180 Life Sciences's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Johnson and Johnson | United States 58.90 % |
| Beone Medicines Ltd | United States 54.39 % |
| Merck and Co Inc | EMEA 21.50 % |
| Pfizer Inc | United States 63.93 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for 180 Life Sciences Corp.
180 Life Sciences's Position in Industry Market Structure
Market-capitalization share and concentration across all 99 companies in 180 Life Sciences's industry classification, broader than the peer set above. Market cap in millions of $.180 Life Sciences ranks #0 of 99 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,624, indicating a moderately concentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | American Express Company | 220,206 | 36.58 % |
| 2 | Nu Holdings Ltd | 60,655 | 10.08 % |
| 3 | Strategy Inc | 44,275 | 7.35 % |
| 4 | Coinbase Global Inc | 35,850 | 5.96 % |
| 5 | Federal National Mortgage Association Fannie Mae | 1,234 | 5.2% |
| 6 | Synchrony Financial | 1,234 | 5.2% |
| 7 | Sofi Technologies Inc | 1,234 | 5.2% |
| 8 | Eason Technology Limited | 1,234 | 5.2% |
| 9 | Circle Internet Group Inc | 1,234 | 5.2% |
| 10 | Federal Home Loan Mortgage Corporation | 1,234 | 5.2% |
| 0 | 180 Life Sciences Corp | 150 | 0.00 % |
Market cap and industry share for the rest of 180 Life Sciences's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-08-15.
180 Life Sciences's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Miscellaneous Financial Services industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (127 companies). See the full Miscellaneous Financial Services industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 3.70 % | 39.33 % (avg) | -35.6 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | 7.22 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 0.00 % | 5.13 % (avg) | -5.1 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
180 Life Sciences's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | -0.49 % | -2.84 % | -21.81 % | -28.61 % | -28.00 % | -155.93 % | -93.48 % | -47.23 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
180 Life Sciences's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 1,624 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 5.13 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on 180 Life Sciences's dedicated Suppliers and Customers pages, not here.
180 Life Sciences's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 238.8 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-49.3% annualized vs trailing 12 months).
Opportunities
- A meaningful share of competitors (47.20 %) show financial-distress signals, a possible opening to gain share.
Threats
- Industry dominated by American Express Company, holding 36.58 % of industry market cap.
Methodology: see Methodology: SWOT Analysis.
180 Life Sciences's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| 180 Life Sciences Corp | 1.15 | 5.93 | 0.59 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
Sign in to see all peers for 180 Life Sciences Corp.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
180 Life Sciences's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| 180 Life Sciences Corp | Q2 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| PEERS TOTAL | +8.7 % | +8.8 % |
Sign in to see all peers for 180 Life Sciences Corp.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
180 Life Sciences's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| 180 Life Sciences Corp | Q2 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
Sign in to see all peers for 180 Life Sciences Corp.
180 Life Sciences's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| 180 Life Sciences Corp | - | - | - |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
Sign in to see all peers for 180 Life Sciences Corp.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
180 Life Sciences's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| 180 Life Sciences Corp | - | 11.15 |
| Johnson and Johnson | 42.68 | 6.95 |
| Beone Medicines Ltd | 948.48 | 102.51 |
| Abbvie Inc | 50.48 | 7.87 |
| Merck and Co Inc | 119.93 | 5.52 |
| Astrazeneca Plc | 28.96 | 5.04 |
| PEERS AVERAGE | 45.19 | 5.95 |
Sign in to see all peers for 180 Life Sciences Corp.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.